ACS Chemical Neuroscience · 2019 · 50 citations · 32 references
MedicineNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyMonoamine NeurochemistryNeurodegenerative Disease ImagingNeurodegenerative DiseasesNeurodegenerative DisordersNuclear Medicine ImagingPositron Emission TomographyEnzyme Inhibition AssaysIn Vivo ImagingTau Protein AggregationTau Uptake
[18F]AV-1451 is one of the most widely used radiotracers for positron emission tomography (PET) imaging of tau protein aggregates in neurodegenerative disorders. While the radiotracer binds with high affinity to tau neurofibrillary tangles, extensive clinical studies have simultaneously revealed off-target tracer accumulation in areas of low tau burden such as the basal ganglia and choroid plexus. Though there are a number of possible reasons for this accumulation, it is often attributed to off-target binding to monoamine oxidase (MAO). In this paper, we investigate the association between [18F]AV-1451 and MAO through (i) enzyme inhibition assays, (ii) autoradiography with postmortem tissue samples, and (iii) nonhuman primate PET imaging. We confirm that [18F]AV-1451 is a weak inhibitor of MAO-A and -B and that MAO inhibitors can alter binding of [18F]AV-1451 in autoradiography and in vivo PET imaging.
32
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Susan Landau, Suzanne L. Baker, Andy Horng et al. · NeuroImage · 2017 · 483 citations · Full text
Medicine, Neurology, Neuroscience +12